ClinicalTrials.gg
CompletedNCT01974440SELENEUpdated May 25, 2025Results posted

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

A Phase 3 interventional study of Bendamustine and Rituximab in Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 135 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing ibrutinib in Lymphoma — 2 open to participants now, 4 under way, none of them phase 3. ibrutinib · Lymphoma.

Enrollment
2nd of 19
403 · median 80
Started
2014
with 2 others
Phase 3
5 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
3 of 19
Janssen Research & Development, LLC

Among the 19 studies testing ibrutinib in Lymphoma, this one is the 2nd largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 7th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 19 studies testing ibrutinib in Lymphoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing ibrutinib in Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.

Read the detailed description

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in approximately 400 adult participants with follicular lymphoma or marginal zone lymphoma. The study will include the following phases: Screening, Treatment, and a Post-treatment Follow-up. Eligible participants will be randomly assigned in a 1:1 ratio to either treatment Arm A (background immune-chemotherapy + placebo) or treatment Arm B (background immune-chemotherapy + 560 milligram [mg] of ibrutinib). All participants will receive 6 cycles of background immune-chemotherapy with either BR or R-CHOP in combination with either placebo (Arm A) or ibrutinib (Arm B). Selection of background immune-chemotherapy will be based on prior treatment history and cardiac function. After completion of background immune-chemotherapy, study drug (ibrutinib or placebo) will continue until disease progression, unacceptable toxicity, or study end, whichever comes first. Assessment of tumor response and progression will be conducted in accordance with the Revised Response Criteria for Malignant Lymphoma. Serial pharmacokinetic (study of what a drug does to the body) blood samples will be collected. Safety will be assessed throughout the study.

03

Conditions studied

  • Lymphoma

Keywords

  • Lymphoma
  • Follicular lymphoma
  • Marginal zone lymphoma
  • Indolent Non-Hodgkin lymphoma
  • PCI-32765
  • Ibrutinib
  • Bendamustine
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
  • R-CHOP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of B-cell indolent Non-Hodgkin lymphoma with histological subtype limited to follicular lymphoma or marginal zone lymphoma, at initial diagnosis and without evidence of pathological transformation or clinical signs suggesting transformation
  • At least 1 prior treatment with a CD20 antibody combination chemo-immunotherapy regimen
  • Disease that has or was refractory after prior chemo-immunotherapy
  • At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma 2007
  • performance status grade 0 or 1
  • Laboratory values within protocol-defined parameters
  • Agrees to protocol-defined use of effective
  • Men must agree not to donate sperm during and after the study for 6 months after the last dose of bendamustine, 12 months after the last dose of rituximab, or 3 months after the last dose of study medication, whichever is later
  • Women of must have a negative serum or urine pregnancy test at Screening

Exclusion criteria

Exclusion Criteria:

  • Prior treatment according to protocol-defined criteria
  • Unable to receive background chemotherapy based on prior treatment history and cardiac function
  • Known central nervous system lymphoma
  • Diagnosed or treated for other than indolent Non-Hodgkin lymphoma
  • History of stroke or intracranial hemorrhage within 6 months prior to randomization
  • Requires anticoagulation with warfarin or equivalent Vitamin K antagonists
  • Requires treatment with strong inhibitors
  • cardiovascular disease
  • Known history of or active virus (HCV; ribonucleic acid [RNA] polymerase chain reaction [PCR]-positive) or active virus (HBV; DNA PCR-positive) infection or any uncontrolled active systemic infection requiring intravenous antibiotics
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
  • Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
403 participants (actual)

Study arms

  • Placebo comparator
    Treatment Arm A

    Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab \[BR\] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]) for 6 cycles + placebo.

    Drug: Bendamustine · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Placebo

  • Experimental
    Treatment Arm B

    Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).

    Drug: Bendamustine · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: PCI-32765 (Ibrutinib)

Interventions

  • 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.

  • 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

  • 750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

  • 50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

  • 1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.

  • 100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.

  • 560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.

  • DrugPlacebo

    Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.

06

What researchers measure

Primary outcomes

  1. Primary Analysis: Progression Free Survival (PFS): Stratified Analysis

    PFS was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from complete response (CR) or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 centimeters (cm) in any axis, 50% increase in sum of product of diameters (SPD) of greater than (\>) 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

    Time frame: Up to 8 years

  2. Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)

    PFS in MZL participants was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from CR or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by \>=50% of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

    Time frame: Up to 8 years

Secondary outcomes

  1. Primary Analysis: Overall Survival (OS): Stratified Analysis

    OS was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

    Time frame: Up to 8 years

  2. Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL

    OS in MZL participants was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

    Time frame: Up to 8 years

  3. Primary Analysis: Complete Response Rate (CRR): Stratified Analysis

    CRR was defined as the percentage of participants who achieved a complete response (CR); (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

    Time frame: Up to 8 years

  4. Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL

    CRR in MZL participants was defined as the percentage of participants who achieved a CR (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

    Time frame: Up to 8 years

  5. Primary Analysis: Overall Response Rate (ORR): Stratified Analysis

    ORR was defined as the percentage of participants who achieved a CR or partial response (PR). Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

    Time frame: Up to 8 years

  6. Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL

    ORR in MZL participants was defined as the percentage of participants who achieved a CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

    Time frame: Up to 8 years

  7. Primary Analysis: Duration of Response (DOR): Stratified Analysis

    DOR was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

    Time frame: Up to 8 years

  8. Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL

    DOR in MZL participants was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

    Time frame: Up to 8 years

  9. Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire

    Time-to-worsening in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

    Time frame: Up to 8 years

  10. Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL

    TTW in MZL participants in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

    Time frame: Up to 8 years

  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication.

    Time frame: Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)

  12. Number of Participants With TEAEs: Participants With MZL

    Number of MZL participants with TEAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication.

    Time frame: Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)

07

Results

Posted Apr 14, 2023

Participant flow

Participants were stratified by background chemotherapy treatment (bendamustine and rituximab \[BR\] or combination or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]), refractory versus relapsed disease, Indolent non-Hodgkin lymphoma histology, and number of prior lines of therapy.

Participant flow — Overall Study
MilestonePlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Started201202
Safety analysis set199201
Participants with marginal zone lymphoma (mzl)2828
Participants with follicular lymphoma (fl)173174
Completed6165
Not completed140137
Withdrew: Lost to follow-up77
Withdrew: Withdrawal by subject2420
Withdrew: Sponsor decision109110

Outcome measures

PrimaryPrimary Analysis: Progression Free Survival (PFS): Stratified Analysis

PFS was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from complete response (CR) or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 centimeters (cm) in any axis, 50% increase in sum of product of diameters (SPD) of greater than (\>) 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

Time frame:
Up to 8 years
Reported as:
Median · months
Primary Analysis: Progression Free Survival (PFS): Stratified Analysis
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Progression Free Survival (PFS): Stratified Analysis23.75 (20.11 to 31.18)40.51 (32.62 to 52.80)
Statistical analysis
  • Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT · Log Rank · p = 0.0922 · Hazard ratio (hr): 0.806 · 95% CI 0.626 to 1.037
PrimarySupplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)

PFS in MZL participants was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from CR or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by \>=50% of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

Time frame:
Up to 8 years
Reported as:
Median · months
Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)91.63 (9.23 to NA)NA (49.25 to NA)
Statistical analysis
  • Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT · Log Rank · p = 0.4505 · Hazard ratio (hr): 0.725 · 95% CI 0.312 to 1.682
SecondaryPrimary Analysis: Overall Survival (OS): Stratified Analysis

OS was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

Time frame:
Up to 8 years
Reported as:
Median · months
Primary Analysis: Overall Survival (OS): Stratified Analysis
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Overall Survival (OS): Stratified AnalysisNA (94.19 to NA)NA (NA to NA)
SecondarySupplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL

OS in MZL participants was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

Time frame:
Up to 8 years
Reported as:
Median · months
Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZLNA (75.86 to NA)NA (NA to NA)
SecondaryPrimary Analysis: Complete Response Rate (CRR): Stratified Analysis

CRR was defined as the percentage of participants who achieved a complete response (CR); (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

Time frame:
Up to 8 years
Reported as:
Number · percentage of participants
Primary Analysis: Complete Response Rate (CRR): Stratified Analysis
percentage of participantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Complete Response Rate (CRR): Stratified Analysis50.255
SecondarySupplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL

CRR in MZL participants was defined as the percentage of participants who achieved a CR (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

Time frame:
Up to 8 years
Reported as:
Number · percentage of participants
Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL
percentage of participantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL60.764.3
SecondaryPrimary Analysis: Overall Response Rate (ORR): Stratified Analysis

ORR was defined as the percentage of participants who achieved a CR or partial response (PR). Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

Time frame:
Up to 8 years
Reported as:
Number · percentage of participants
Primary Analysis: Overall Response Rate (ORR): Stratified Analysis
percentage of participantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Overall Response Rate (ORR): Stratified Analysis90.591.6
SecondarySupplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL

ORR in MZL participants was defined as the percentage of participants who achieved a CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

Time frame:
Up to 8 years
Reported as:
Number · percentage of participants
Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL
percentage of participantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL82.189.3
SecondaryPrimary Analysis: Duration of Response (DOR): Stratified Analysis

DOR was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis.

Time frame:
Up to 8 years
Reported as:
Median · months
Primary Analysis: Duration of Response (DOR): Stratified Analysis
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Duration of Response (DOR): Stratified Analysis21.68 (17.61 to 32.36)44.32 (32.89 to 60.02)
SecondarySupplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL

DOR in MZL participants was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: \>=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL.

Time frame:
Up to 8 years
Reported as:
Median · months
Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL89.17 (42.48 to NA)NA (73.23 to NA)
SecondaryPrimary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire

Time-to-worsening in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

Time frame:
Up to 8 years
Reported as:
Median · months
Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire37.03 (24.21 to 48.33)24.84 (14.95 to 31.28)
SecondarySupplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL

TTW in MZL participants in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

Time frame:
Up to 8 years
Reported as:
Median · months
Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL
monthsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL36.83 (4.86 to NA)58.91 (5.82 to 85.88)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication.

Time frame:
Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Number of Participants With Treatment-emergent Adverse Events (TEAEs)197199
SecondaryNumber of Participants With TEAEs: Participants With MZL

Number of MZL participants with TEAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication.

Time frame:
Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs: Participants With MZL
ParticipantsPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
Number of Participants With TEAEs: Participants With MZL2828

Adverse events

Collected over All Serious AEs and Other (Not Including Serious) AEs: for Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after last dose of study medication (up to 8 years 8 months); all cause mortality: From Day 1 up to end of study (up to 9 years 1 month). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Chemoimmunotherapy (CIT)61/201 (30.3%)76/199 (38.2%)196/199 (98.5%)
Ibrutinib + CIT65/202 (32.2%)113/201 (56.2%)198/201 (98.5%)
Most frequent serious events
Showing 10 of 226
Most frequent serious events
EventPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
PneumoniaInfections and infestations9/19920/201
PyrexiaGeneral disorders5/19916/201
Febrile NeutropeniaBlood and lymphatic system disorders7/19913/201
SepsisInfections and infestations4/1998/201
Urinary Tract InfectionInfections and infestations3/1997/201
NeutropeniaBlood and lymphatic system disorders1/1995/201
CellulitisInfections and infestations3/1995/201
Acute Kidney InjuryRenal and urinary disorders0/1995/201
Herpes ZosterInfections and infestations4/1993/201
Atrial FibrillationCardiac disorders2/1994/201
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPlacebo + Chemoimmunotherapy (CIT)Ibrutinib + CIT
NauseaGastrointestinal disorders78/199103/201
DiarrhoeaGastrointestinal disorders69/199102/201
NeutropeniaBlood and lymphatic system disorders69/19975/201
FatigueGeneral disorders60/19973/201
RashSkin and subcutaneous tissue disorders33/19968/201
PyrexiaGeneral disorders45/19960/201
VomitingGastrointestinal disorders40/19957/201
CoughRespiratory, thoracic and mediastinal disorders40/19957/201
ConstipationGastrointestinal disorders54/19933/201
AnaemiaBlood and lymphatic system disorders39/19950/201

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Chemoimmunotherapy (CIT)Ibrutinib + CITTotal
Mean58.7 ± 12.758.9 ± 11.8658.8 ± 12.27
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Chemoimmunotherapy (CIT)Ibrutinib + CITTotal
Female10289191
Male99113212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Chemoimmunotherapy (CIT)Ibrutinib + CITTotal
Hispanic or Latino141630
Not Hispanic or Latino173178351
Unknown or Not Reported14822
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Chemoimmunotherapy (CIT)Ibrutinib + CITTotal
American Indian or Alaska Native000
Asian5968127
Native Hawaiian or Other Pacific Islander000
Black or African American044
White135126261
More than one race101
Unknown or Not Reported6410
Region of Enrollment
Region of Enrollment(Participants)Placebo + Chemoimmunotherapy (CIT)Ibrutinib + CITTotal
ARGENTINA2810
AUSTRALIA211637
BELGIUM4913
BRAZIL123
CHINA312657
FRANCE13821
GERMANY5813
ISRAEL161733
ITALY6511
JAPAN152742
POLAND448
RUSSIAN FEDERATION11920
SOUTH KOREA121426
SPAIN13720
SWEDEN101
TURKEY11920
UKRAINE628
UNITED KINGDOM101020
UNITED STATES192140
08

Study locations

135 sites
  • Gilbert, Arizona, United States
  • Campbell, California, United States
  • Duarte, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Ocala, Florida, United States
  • Chicago, Illinois, United States
  • Maywood, Illinois, United States
  • Indianapolis, Indiana, United States
  • Westwood, Kansas, United States
  • Lexington, Kentucky, United States
  • Lafayette, Louisiana, United States
  • Scarborough, Maine, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Battle Creek, Michigan, United States
  • Detroit, Michigan, United States
  • Saint Louis Park, Minnesota, United States
  • Denville, New Jersey, United States
  • New York, New York, United States
  • Hickory, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Bend, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Sioux Falls, South Dakota, United States
  • Houston, Texas, United States
  • Lubbock, Texas, United States
  • Spokane, Washington, United States
  • Green Bay, Wisconsin, United States
  • Buenos Aires, Argentina
  • Ciudad Autonoma Buenos Aires, Argentina
  • Cordoba, Argentina
  • La Capital, Argentina
  • Mendoza, Argentina
  • Santa Fe, Argentina
  • Adelaide, Australia
  • Fitzroy, Australia
  • Heidelberg, Australia
  • South Brisbane, Australia
  • Wahroonga, Australia
  • Westmead, Australia
  • Anderlecht, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Namur, Belgium
  • Wilrijk, Belgium
  • Porto Alegre, Brazil
  • Rio De Janeiro, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Beijing, China
  • Chengdu, China
  • Guangzhou, China
  • Hangzhou, China
  • Harbin, China
  • Nanjing, China
  • Shanghai, China
  • Tianjin, China
  • Nice Cedex 2, France
  • Paris, France
  • Pessac, France
  • Pierre Benite, France
  • Rennes, France
  • Berlin, Germany
  • Gießen, Germany
  • Göttingen, Germany
  • Ludwigshafen, Germany
  • Magdeburg, Germany
  • Mainz, Germany
  • Munchen, Germany
  • Wiesbaden, Germany
  • Hadera, Israel
  • Haifa, Israel
  • Jerusalem, Israel
  • Nahariya, Israel
  • Netanya, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Chuo Ku, Japan
  • Hiroshima shi, Japan
  • Isehara, Japan
  • Kobe, Japan
  • Nagoya-shi, Japan
  • Osaka Sayama shi, Japan
  • Sapporo-shi, Japan
  • Sendai shi, Japan
  • Suita-shi, Japan
  • Tokyo, Japan
  • Jeollanam-do, Korea, Republic of
  • Seoul, Korea, Republic of
  • Gdynia, Poland
  • Olsztyn, Poland
  • Warszawa, Poland
  • Bayamon, Puerto Rico
  • Ponce, Puerto Rico
  • San Juan, Puerto Rico

Showing the first 100 of 135 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in May 2022, 99 months.

Results were first posted in Apr 2023, 10 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 99 months is above that.

Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2013
First posted
Nov 1, 2013
StartActual
Jan 31, 2014
Primary completionActual
May 30, 2022
CompletionActual
Jun 21, 2023
Results first posted
Apr 14, 2023
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01974440
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 1, 2013
Start date
Jan 31, 2014
Primary completion
May 30, 2022
Completion
Jun 21, 2023
Results posted
Apr 14, 2023
Last update
May 25, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion